Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

about

PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies

P2860

Q57174165-3032298E-D353-45BE-9754-C38492A14FD4

P2860

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

Item

http://www.wikidata.org/entity/Q53134069

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

@en

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

@nl

type

Item

label

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

@en

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

@nl

prefLabel

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

@en

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

@nl

P1476

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

@en

P2093

Hui Ma

http://www.w3.org/2001/XMLSchema#string

Li Chen

http://www.w3.org/2001/XMLSchema#string

Liang Li

http://www.w3.org/2001/XMLSchema#string

Qinglai Xia

http://www.w3.org/2001/XMLSchema#string

Wenjing Hou

http://www.w3.org/2001/XMLSchema#string

Xuening Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?

Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study.

The hOGG1 Ser326Cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls.

Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis

Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis.

Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy

CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis

Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis.

Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients.

A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.

P2888

s13277-014-1606-9

P304

4629-4635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S13277-014-1606-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24414486

http://www.w3.org/2001/XMLSchema#string

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

about

P2860

P2860

Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698